Personalis (NASDAQ:PSNL) Stock Price Up 6.5% - What's Next?

Key Points

• Personalis, Inc. shares surged 6.5% on Thursday, reaching a last traded price of $5.74, despite a significant drop in trading volume compared to the average.
• Analyst ratings reflect a mix of opinions, with five analysts giving a "Buy" rating and a consensus price target of $7.42, while Wall Street Zen downgraded the stock to a "sell" rating.
• The company reported a quarterly loss of ($0.23) EPS, exceeding analysts' expectations, although revenue fell short of forecasts, highlighting ongoing financial challenges.

Personalis, Inc. (NASDAQ:PSNL - Get Free Report) shares shot up 6.5% on Thursday . The stock traded as high as $5.64 and last traded at $5.74. 72,238 shares were traded during mid-day trading, a decline of 93% from the average session volume of 1,042,834 shares. The stock had previously closed at $5.39.

Analyst Ratings Changes

Several research firms have weighed in on PSNL. Wall Street Zen lowered shares of Personalis from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. Guggenheim began coverage on shares of Personalis in a research note on Thursday, May 15th. They set a "buy" rating and a $6.00 target price for the company. HC Wainwright reiterated a "buy" rating and issued a $8.50 price target on shares of Personalis in a research report on Monday. Finally, BTIG Research set a $6.00 target price on shares of Personalis in a report on Wednesday, August 6th. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $7.42.

Personalis Stock Performance

The stock has a market capitalization of $544.14 million, a P/E ratio of -4.80 and a beta of 1.76. The stock's fifty day simple moving average is $5.56 and its two-hundred day simple moving average is $4.84.

Personalis (NASDAQ:PSNL - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.02. The firm had revenue of $17.20 million for the quarter, compared to the consensus estimate of $20.12 million. Personalis had a negative net margin of 113.70% and a negative return on equity of 47.57%. Personalis has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, analysts expect that Personalis, Inc. will post -1.4 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Personalis during the 4th quarter valued at $28,000. Legal & General Group Plc acquired a new position in shares of Personalis during the 2nd quarter valued at $30,000. Ameritas Investment Partners Inc. acquired a new position in shares of Personalis during the 2nd quarter valued at $34,000. BNP Paribas Financial Markets lifted its position in shares of Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company's stock valued at $42,000 after acquiring an additional 5,177 shares during the period. Finally, Focus Partners Wealth acquired a new position in shares of Personalis during the 1st quarter valued at $47,000. Institutional investors and hedge funds own 61.91% of the company's stock.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.